Pharmacokinetics and pharmacodynamics of intravenous delafloxacin in healthy subjects: model-based dose optimization
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00428-24 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Jiong-Xian Lv und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Fluoroquinolones, Anti-Bacterial Agents, Microbial Sensitivity Tests, Monte Carlo Method. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Delafloxacin, a fluoroquinolone antibiotic to treat skin infections, exhibits a broad-spectrum antimicrobial activity. The first randomized, open-label phase I clinical trial was conducted to assess the safety and pharmacokinetics (PK) of intravenous delafloxacin in the Chinese population. A population pharmacokinetic (PopPK) model based on the clinical trial was conducted by NONMEM software. Monte Carlo simulation was performed to evaluate the antibacterial effects of delafloxacin at different doses in different Chinese populations. The PK characteristics of delafloxacin were best described by a three-compartment model with mixed linear and nonlinear clearance. Body weight was included as a covariate in the model. We simulated the AUC 0-24h in a steady state at five doses in patient groups of various weights. The results indicated that for patients weighing 70 kg and treated with methicillin-resistant Staphylococcus aureus (MRSA) infections, a minimum dose of 300 mg achieved a PTA > 90% at MIC 90 of 0.25 µg/mL, suggesting an ideal bactericidal effect. For patients weighing less than 60 kg, a dose of 200 mg achieved a PTA > 90% at MIC 90 of 0.25 µg/mL, also suggesting an ideal bactericidal effect. Additionally, this trial demonstrated the high safety of delafloxacin in single-dose and multiple-dose groups of Chinese. Delafloxacin (300 mg, q12h, iv) was recommended for achieving optimal efficacy in Chinese bacterial skin infections patients. To ensure optimal efficacy, an individualized dose of 200 mg (q12h, iv) could be advised for patients weighing less than 60 kg, and 300 mg (q12h, iv) for those weighing more than 60 kg.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Clinical Pharmacology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
ORCID-Profile: Jiong-Xian Lv, Yu-Wen Su
Zitieren
APA
Lv, J. X., Huang, Y. H., Kafauit, F., Wang, Y. H., Su, C., Ma, J. H., Xu, Y., Huang, C. C., Zhang, Q., & Su, Y. W. (2024). Pharmacokinetics and pharmacodynamics of intravenous delafloxacin in healthy subjects: model-based dose optimization. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00428-24
Vancouver
Lv JX, Huang YH, Kafauit F, Wang YH, Su C, Ma JH, et al. Pharmacokinetics and pharmacodynamics of intravenous delafloxacin in healthy subjects: model-based dose optimization. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00428-24
BibTeX
@article{Lv2024,
author = {Lv, Jiong-Xian and Huang, Yi-Huan and Kafauit, Farah and Wang, Yuan-Hui and Su, Chang and Ma, Jun-Heng and Xu, Yan and Huang, Chao-Chao and Zhang, Qing and Su, Yu-Wen},
title = {Pharmacokinetics and pharmacodynamics of intravenous delafloxacin in healthy subjects: model-based dose optimization},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00428-24}
}
EUVIMED